RxDoctor Payments Data

Krista Edelman, MD

Gastroenterology · Richmond, VANPI 1417249434

Payments from drug & device makers

$7,186in general payments, 2019–2025

Across 373 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$708
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$682
  • Johnson & Johnson$457
  • Sanofi$271
  • Pfizer$235
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$7,03498%
  • Education$1522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,186 in reported general payments places this provider in the 60th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$127,925
Medicare patients
477
Services billed
937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Entyvio PenVedolizumab11$91,682
XifaxanRifaximin36$75,095
CreonLipase/Protease/Amylase14$43,429
LinzessLinaclotide24$31,047
Mesalamine26$22,437
MotegrityPrucalopride Succinate16$14,828
ClenpiqSod Picosulf/Mag Ox/Citric Ac55$9,250
Dexlansoprazole DrDexlansoprazole23$9,185
Colestipol Hcl54$4,310
Omeprazole286$3,718
Mesalamine ErMesalamine15$3,348
Pantoprazole Sodium205$2,530
Budesonide DrBudesonide16$2,318
Famotidine180$2,210
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl140$1,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$682$75,09536 claims
AbbVieCreon, Linzess$3,379$74,47638 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$708$14,82816 claims
Ferring Pharmaceuticals Inc.Clenpiq$117$9,25055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →